Quantifying the use of bioresources for promoting their sharing in scientific research by Laurence Mabile et al.
Mabile et al. GigaScience 2013, 2:7
http://www.gigasciencejournal.com/content/2/1/7REVIEW Open AccessQuantifying the use of bioresources for
promoting their sharing in scientific research
Laurence Mabile1,2, Raymond Dalgleish3, Gudmundur A Thorisson3,4, Mylène Deschênes5, Robert Hewitt6,
Jane Carpenter7, Elena Bravo8, Mirella Filocamo9, Pierre Antoine Gourraud10, Jennifer R Harris11, Paul Hofman12,
Francine Kauffmann13,14, Maria Angeles Muñoz-Fernàndez15, Markus Pasterk16, Anne Cambon-Thomsen1,2*
and BRIF working groupAbstract
An increasing portion of biomedical research relies on the use of biobanks and databases. Sharing of such
resources is essential for optimizing knowledge production. A major obstacle for sharing bioresources is the lack of
recognition for the efforts involved in establishing, maintaining and sharing them, due to, in particular, the absence
of adequate tools. Increasing demands on biobanks and databases to improve access should be complemented
with efforts of end-users to recognize and acknowledge these resources. An appropriate set of tools must be
developed and implemented to measure this impact.
To address this issue we propose to measure the use in research of such bioresources as a value of their impact,
leading to create an indicator: Bioresource Research Impact Factor (BRIF). Key elements to be assessed are: defining
obstacles to sharing samples and data, choosing adequate identifier for bioresources, identifying and weighing
parameters to be considered in the metrics, analyzing the role of journal guidelines and policies for resource citing
and referencing, assessing policies for resource access and sharing and their influence on bioresource use. This
work allows us to propose a framework and foundations for the operational development of BRIF that still requires
input from stakeholders within the biomedical community.
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Bioresources as key players in biomedical research
A growing portion of research relies on using sample
collections and databases [1]. Sharing such resources is
essential for optimizing knowledge production. This is
especially true in biological and medical sciences with
the development of large-scale biology in the –omics era
[2]. The size and complexity of the collections needed to
promote translational research typically extends far
beyond the scope of individual research projects and the
need to produce these valuable data is being met by
contemporary bioresource facilities.* Correspondence: anne.cambon-thomsen@univ-tlse3.fr
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reproduction in any medium, provided the orBioresources are defined as biological samples with
associated data (medical/epidemiological, social), and
databases independent of physical samples, and other
biomolecular and bioinformatics research tools (Table 1).
A commitment to share the information content of
bioresources with the research community is paramount
to advancing translational research [3,4]. The 2011 joint
statement of 17 major national health research funders
sent a powerful signal that health research resources
must be shared to maximize the potential of publicly
funded resources [5-9]: “Funders agree to promote
greater access to and use of data in ways that are: Equit-
able…, Ethical…, Efficient”. Although this statement
gives a vision, principles, goals and aspirations, it does
not indicate any practical tool or instrument to reach
the objectives. Therefore, it is important to develop
incentives that will support and promote this sharing if
we are to realize the vision which funders hope toLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Definitions
Designation Definition
BIOSPECIMEN A quantity of tissue, blood, urine, or other human-derived material. A biospecimen can comprise subcellular structures,
cells, tissue (e.g. bone, muscle, connective tissue, and skin), organs (e.g., liver, bladder, heart, and kidney), blood,
gametes (sperm and ova), embryos, fetal tissue, and waste (urine, feces, sweat, hair and nail clippings, shed epithelial
cells, and placenta). Portions or aliquots of a biospecimen are referred to as samples (NCI* Best Practices working
definition).
ANNOTATION Database information designed to capture experimental or inferential results. Often referring to annotation of
sequence data. Experimental annotation is supported by peer-reviewed wet-lab experimental evidence. Inferential
annotation of sequence data is by inference (where the source molecule or its product(s) have not been the subject of
direct experimentation) (from NCBI third party Annotation database).
DATABASE An organized set of data or collection of files that can be used for a specified purpose (definition from A dictionary of
Epidemiology 4th Ed. by J.M. Last).




Service providers and repositories of the living cells, genomes of organisms, and information relating to heredity and
the functions of biological systems. BRCs contain collections of culturable organisms (e.g. genomes, plasmids, viruses,
cDNAs), viable but not yet culturable organisms cells and tissues, as well as databases containing molecular,
physiological and structural information relevant to these collections and related bioinformatics… (from OECD*** Best
Practise Guidelines for BRCs, 2007).
BIOBANK A collection of biological material and the associated data and information stored in an organised system, for a
population or a large subset of a population (OECD** Glossary of statistical terms).
BIOSPECIMEN RESOURCE A collection of human specimens and associated data for research purposes, the physical entity in which the collection
is stored, and all associated processes and policies. Biospecimen resources vary considerably, ranging from formal
institutions to informal collections in a researcher’s freezer (NCI Best Practices working definition).
BIORESOURCES Biological samples with associated data (medical/epidemiological, social), databases independent of physical samples
and other biomolecular and bioinformatics research tools (BRIF group working definition).
*From National Cancer Institute Best Practices for Biospecimen Resources.
** National Center for Biotechnology Information.
***Organisation for Economic Co-operation and Development.
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that recognizes the specific contribution of bioresources
in the development of novel scientific knowledge. Whilst
promoting measures to improve access to biobanks and
databases, we must also develop policies mandating end-
users to recognize and acknowledge the provenance of
these resources. An appropriate set of tools is needed to
implement such policies. Some tools currently exist, but
an insufficient level of coordination and systematic
implementation makes it difficult to see their positive
impact on the overall organization of health research
activities [6,12].
The BRIF initiative
The concept of a Bioresource Research Impact Factor
(BRIF) was introduced in 2003 [13], and later further
developed [14,15]. The BRIF initiative was set up to con-
struct an adequate framework and provide a set of tools
that will allow an objective measure of the actual re-
search utilization of bioresources as a significant compo-
nent for establishing their reliability and sustainability.
An international working group was established to
develop the BRIF, consisting of 134 members from 22
countries, most of whom are either European (86) or
North-American (31). This group was further divided
into five relevant thematic sub-groups: i) BRIF and digital
identifiers, ii) BRIF parameters, iii) BRIF in sharingpolicies, iv) BRIF and journal editors and v) BRIF dissem-
ination [16]. Key issues from the dedicated sub-groups’
work and the first two BRIF workshops are reported here.
Constructing a quantitative tool to evaluate the impact of
a bioresource on research
The BRIF will be modeled, to some degree, on the Journal
Impact Factor (JIF) [17], and will provide guidance and
methodology for optimizing recognition of bioresources,
their use and their sharing at an international level. Such
a tool could be used much more systematically than
“reputation” for evaluating the activity of a bioresource
over time. When taken into account in assessing ‘re-
searchers/contributors’ scientific contribution, this should
increase the use and sharing of bioresources, where in
which a virtuous circle would occur: the highest is the
quality, the most frequent will be the solicitations; the
more one shares, the more one’s impact increases, and
the more one is inclined to share. Although this concept
can be valid for any kind of bioresource, we focus first on
bioresources of human origin.
Stakeholders in bioresources sharing
BRIF aims to be a quantitative indicator filling a gap in
the complex environment of scientific production as-
sessment. Its implementation thus depends on its ability
to meet the requirements of multiple stakeholders and
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and parameters. BRIF could effectively enable traceabil-
ity, thus being useful for all actors involved in the complex
world of bioresources, from the initial collector(s) or initi-
ator(s) to the scientific primary or secondary user(s) on the
one hand; to funding bodies, the general public, scientific
readers, industry and editors on the other hand. Stake-
holders would benefit from the BRIF through the recog-
nition it will generate or through the information it will
offer about the bioresource, its use and the research
results based on it (Figure 1).
Choosing adequate digital identifier schemes
The main difficulties in providing the most reliable assess-
ment of appropriate biobank usage relates to identification
and variable ways of acknowledging bioresources (Table 2).
The process of tracking publications and quantifying their
impact is not straightforward. In order to track the publi-
cations involving a bioresource, it is essential that re-
searchers consistently acknowledge use of the bioresource
by placing a unique and traceable identifier in all relevant
publications in a defined section of the article. To some
extent such tracking is already possible, provided that
authors have acknowledged the bioresource or cited the
bioresources’ publications, and an effort is made to find
appropriate acknowledgements. In order to optimize and
standardize this process, it must be automated to enable a

















General information on the 
Bioresource, its use and the results of 
the research based on it
Figure 1 Actors involved in the complex world of bioresources. The u
of bioresources. The lower panel (purple arrows) shows the various stakeho
upper panel and the purple box the information needs of stakeholders. BR
various dimensions.With the purpose of addressing the various issues re-
ferred to above, bioresources need to be assigned action-
able digital identifiers or IDs [18], and to fulfill the
requirements of the scholarly record, the bioresource ID
should be persistent, globally unique and citable. The
BRIF ID sub-group focuses on exploring and assessing
existing and emerging technical solutions suitable for
bioresource identification, as well as addressing key re-
lated issues, such as what to identify (biobank projects,
sample collections, databases, datasets, etc.) and which
international and independent body (or bodies) should
be responsible for assigning the bioresource ID.
The aim of BRIF is not to create a new identifier
scheme specifically for bioresources, but rather to iden-
tify frameworks that are already established (or well on
their way to becoming so), such as registries for clinical
trial studies and other more general ID schemes [19],
and to subsequently assess them and recommend their
use as appropriate with respect to: i) resource providers
(e.g., what type of IDs to use for biobank projects and
databases); ii) end-users (e.g., editorial guidelines for
authors on how to properly cite biobank projects and
databases using unique resource IDs).
Findings of the sub-group are that the field is already
moving in the expected direction in several areas; most
notably, the DataCite initiative [20] has established a
worldwide data registration agency that reuses and
extends the Digital Object Identifier (DOI) scheme that












pper panel (blue arrows) exhibits the chain of production and sharing
lders involved. The blue box represents the recognition needs for the
IF that bridges the two boxes represents the tool to link these
Table 2 Current key elements impeding proper tracking of bioresources use in scientific literature
Difficulties related to identification and acknowledgement of bioresources Difficulties encountered with marker papers**
- multiplicity of sections where bioresources can be acknowledged (Material & Methods,
Acknowledgements, References…)
- suitable to refer to one type of bioresource but not for
any derived, or secondary bioresources
- bioresource acknowledgement or citation placed outside the title or abstract in the
main paper (or in online supplementary materials) which can therefore only be
detected via full-text mining and is not indexed in Pubmed or Web of Science
- typing errors or approximation of the bioresource name/identification
- multiplicity of names for a given bioresource
- cascade use of resources (e.g. several CEPH* Family samples are part of the Hapmap
which are themselves part of the 1000 Genome Project)
- acknowledgement of persons instead of the bioresource itself
-absence of acknowledgement for the bioresource used (negligence)
- no standardized way to incentivise researchers to acknowledge properly the
bioresource used
*CEPH, Centre d’Etude du Polymorphisme Humain.
**[36].
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sample collections), or born-digital resources (datasets
associated with a resource or generated by its use) can
be assigned data DOIs [23]. This is an important step
towards recognizing the creation and sharing of research
data as a valuable scientific contribution [24]. DOIs
could then serve as first-step identifiers to be used in the
BRIF assessment. Other possibilities that are suitable for
investigation include the World Health Organisation
(WHO) [19], which is already involved in assigning
clinical trials registration numbers, and the Organisation
for Economic Co-operation and Development (OECD).
A closely-related issue is the current lack of global
infrastructure for identifying and acknowledging re-
searchers who contribute to bioresources [25]. The
centralized contributor ID system now being built by
the international Open Researcher and Contributor ID
(ORCID) initiative [26] has been recently launched. It
seems reasonable to assume that this emerging infra-
structure will be at the heart of any attribution
schemes for scientific contributions [27] and therefore
likely to be very relevant for BRIF in the near future.
Datacite and ORCID are now involved in a common
European project, ODIN (the ORCID and DataCite
Interoperability Network) that aims to design an
‘awareness layer’ for persistent author and object iden-
tifiers, notably by providing an Information Architect
and Software Developer. It will explore how to connect
the unique identifiers for persons and datasets across
multiple services and infrastructures for scholarly
communication.
Identifying and weighing parameters, measures and
indicators
Establishing a valuable bioresource requires considerable
time and effort, and in order to provide appropriaterewards and recognition, it is necessary to be able to
measure their utility. There are various ways to do so
such as using a range of indicators at various levels
(biological samples, annotations and associated data,
and search tools), including management indicators
showing that the bioresource is efficiently run and well
utilized; quality indicators such as the quantity of
biospecimens available and the value of samples or
datasets; and indicators of research productivity based
on bioresource use and reuse. Since the purpose of the
bioresources considered here is to enhance health
research productivity, this last set of indicators may
provide the most reliable assessment of appropriate
biobank usage.
With these indicators in mind the BRIF parameters
need to be both objective and easily verifiable, and the
calculation of a BRIF needs to be as simple as possible.
The main identified indicators have been grouped as
follows (see Table 3): 1/age and size of the bioresource;
2/research productivity and sustainability (journals and
papers, grants and patents, institutional funding);
3/sample/data value (follow up of data, diversity, rare-
ness, quality control…); 4/bioresource management
(workflow and efficiency); 5/networking and visibility
of the bioresource. Downstream effects on healthcare
and the economy will not be assessed. An obvious
approach is to use a simple metric based on citation
counts in conjunction with the traditional notion of
journal-level impact. BRIF calculation will have to
provide a measure of the extent to which bioresources
contribute to research. Subsequent surveys are cur-
rently being done to identify and weight key parame-
ters for the evaluation of bioresource impact in
research, as well as to distinguish those that can be
easily tracked and measured to construct the metrics
of a meaningful BRIF.
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resource citing and referencing
A key element for assessing the use and the research im-
pact of bioresources is via their systematic citation in jour-
nal articles. However, today there are no standards and
guidelines for the citation of such resources. Even when au-
thors make an honest attempt to properly acknowledge a
bioresource, the results can be patchy and inconsistent. For
example, the presence of the web address, or uniform re-
source locator (URL) of a database in biomedical papers
provides some evidence of reuse; however, if the URL is not
present in the abstract, then the reference to the database
will not be discoverable via PubMed or other bibliographic
databases which only index abstracts. Hence, journalTable 3 Range of indicators and parameters to take into cons
First-line parameters
1) Age of bioresource
Size of bioresource
2) Indicators of research productivity:
- Quality of the journal (impact factor…)
- Number of articles citing the bioresource itself or the staff
- Cumulated impact factor (or h index) of publications that result from resear
supported by the bioresource
- Number of patents that result from the use of the bioresource
- Distribution of samples having multiple involvement in independent projec
3) Indicators of high value
- Rare disease samples or data / samples with rare characteristics
- Extent and richness of the datasets collected
- Existence of a quality control policy for samples and data
- Compliance with data reporting nomenclatures and sharing standards
- Participation in external assessment programmes such as certification or ac
(ISO certification for example)
- Availability of morphological controls of frozen specimens used for “omics”
programme (biobanks)
4) Indicators of management
- Number of projects supported per year
- Number of biospecimens entering in the biobank / number of biospecimen
distribution to research projects by year
- Number of requests filled per year (to be balanced with the type of resourc
- Number of web page accesses per year for data resources
- Number of material (data) transfer agreements and contracts signed per ye
- Turnaround time for requests
- Time to include new data
- Consent forms
- Data protection measures
5) Indicators of visibility
- Networks
- Catalogues
- General policies of transparency, dissemination, access rules…publishers need to establish a clear policy concerning the
citation and referencing of the contributing bioresource
otherwise, measuring the impact of bioresources will re-
main an imprecise process.
Recognition by journal editors of the need to properly
acknowledge the bioresources utilized, using proper ter-
minology and/or identifiers and agreeing on standards of
citation (format/marker paper, location(s), institutions,
people, etc.) has been extensively discussed. The BRIF
sub-group has initiated a dialogue with the Committee
on Publication Ethics (COPE) and the International
Committee of Medical Journal Editors (ICMJE) [28] in
order to inform journal editors about the BRIF issues
and to promote the modification of editorial guidelinesideration for BRIF
Second-line parameters
- Grants obtained by the users of the bioresource or to
support the bioresource





- Official recognition from Regional/National Health Bodies
creditation
- Number of samples received and distributed per year
s used for - Number of material/data transfer agreements
e)
- Number of contracts or agreements
- Average time from collection to actual use of the
sample (sustainable maintenance)
Other factors:ar
- Return of research policy
- Impact of data cost on inclination to correctly cite the
source of data
- Past achievements of the bioresource…
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Submitted to Biomedical Journals” [28] already exist, a
first proposal has been sent to the ICMJE to be consid-
ered in a future amendment of these requirements.
This proposal highlights some additional requirements
(Table 4) that may be needed to address the editorial
problems concerning bioresources. Furthermore, additional
actions have been designed to sensitize other committees
and institutions concerned with editorial and ethical issues.
Notably, the European Association of Science Editors
(EASE) is presently considering how to include citation of
bioresources in their guidelines.
Assessing policies for resource access and sharing
Attempting to measure the impact of a bioresource is based
upon the assumption that the research resource is actually
being utilized. Use of a bioresource is contingent upon
many factors, but the access and sharing policies certainly
play a major role in facilitating or hindering use. Various
components, such as the level of constraints imposed on
users or the level of user-friendliness of the procedures to
gain access, are pivotal to creating an environment that will
stimulate or discourage using a given bioresource.
Appropriate indices to consider in implementing a strat-
egy to measure and compare the impact of bioresources
[29] include, sharing policies, access and publication pol-
icies and the agreements that support the ‘transaction’ of
sharing material or data, as well as community standards,
such as those indexed by BioSharing [30]. Through such
guidelines or contracts, a bioresource can impose require-
ments on users that would enable the measure of its
impact. Two dimensions are likely to contribute to the
measure of the bioresource impact: dissemination and ‘con-
trol’ measures. Publications, academic presentations and
other less traditional means of disseminating research
results are critical. Bioresources must therefore ensure thatTable 4 Main suggestions for the Uniform Requirements for M
Editing for Biomedical Publication (www.icmje.org)
Guideline text section
in II. ETHICAL CONSIDERATIONS IN THE CONDUCT
AND REPORTING OF RESEARCH
‘Biobankers should alw
useful for the conduc
should also be report
II.A Authorship and contributorship
II.A.2 Contributors listed in
acknowledgements:












project.’users will recognize the resources that were used in what-
ever means the researchers use to communicate their
results to the scientific community or to the public. This
recognition must occur in such a way that will allow a
systematic search to track use as described above.
Bioresources may also require users to report on their
use back to the bioresource (e.g., sending their publication
or a summary report). However, a balance must be struck
between imposing a series of requirements on users and on
bioresource managers and still maintaining conditions that
foster resource use.
The level of control that the bioresource can exercise
over the various secondary uses of its content is another
factor that can enable the measurement of its scientific
impact. In order for a bioresource to track the use of its
content it must ensure that users comply with its dissemi-
nation requirements. This is particularly challenging for re-
search databases where the data can be copied and
circulated easily and ad infinitum. In a context where inter-
national collaboration is increasing and pooling of research
resources is necessary to conduct research, for example on
complex diseases and health, it is difficult for the
bioresource to track all uses. The identity of the source of a
material may be lost in the chain of multiple exchanges and
amalgamation with others unless the link to a “mother re-
source” is traceable. A bioresource can thus require that
users do not share the material/data with third parties.
Under such circumstances, it is expected that users will
have to deal directly with the initial bioresource provider to
gain access, and will thus have the same requirements im-
posed upon them to recognize the original resources. Once
again, a balance must be struck between imposing con-
straints on users and making use of the bioresource appeal-
ing. However, if the correct balance is reached, specific
issues persist relating to databases where no physical entity
is provided. To some extent, commercial data providersanuscripts Submitted to Biomedical Journals: Writing and
Proposition
ays be acknowledged for their contribution in providing "bioresources"
t of the study. The name of the biobank (and identifier, if available)
ed here in full.’
s and/or biobanks used as sources of samples and/or data (and their
Bioresources include both biological samples with associated data
ical, social) and biomolecular research tools. The biosamples and
s include any "physical" specimen derived from biological organisms, as
ity binder collections, clone collections, siRNA and microarrays libraries.
e any data directly or undirectly derived from biosamples such as
ific-databases, registries of disease patients and any specific tool for
tion of biobanked samples.’
ional, European and/or international infrastructure that has evaluated the
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data. A breach of corresponding terms and conditions
might then allow the data provider to restrict future access.
As to those databases that provide free access, large organi-
zations can organize and support a number of control ac-
tions [29]. Small data providers, for example, curators of
Locus Specific Databases for a small number of genes, have
fewer opportunities to exert access control and simply rely
on database copyright protection [31]. Given the delicate
balance required between stimulating usage and supporting
the capacity to measure the impact, the BRIF sub-group
proposes to develop an appropriate set of standard tools
that could eventually be integrated in the overall access and
sharing policies of bioresources.
Conclusions
Perspectives: Current endeavors for practical
development and implementation of BRIF
Pilot actions
To allow bioresource recognition to become rapidly
entrenched in everyday research practices, it is essential to
test the feasibility of the various aspects of the BRIF
through several small-sized pilot studies each focusing on
specific issues, such as the citation modalities, especially
exploring the feasibility of a specific field for bioresources
in electronic submission systems, the identifier entity, the
authors compliance. This is being initiated with the help of
volunteer consortiums (i.e., eagle-i [32], BioSHaRE [33],
P3G [34], BiOBANQUES [35]), and being open to external
proposals.
Outreach
The international outreach of the initiative is presently lim-
ited as an unbalanced geopolitical representation that has
been mobilized so far in the BRIF working group. A dis-
semination and open access policy to the participation in
this initiative is thus necessary and this paper aims to en-
courage this. Better geographical representation, contact
with other networks and initiatives that could produce syn-
ergetic actions, and solicitation of international journal edi-
tors committees and institutional scientific evaluation
boards involved in producing incentives and guidance to-
wards researchers and authors may each contribute to bet-
ter tailor the BRIF tool as required.
Metrics
Once a solid framework for bioresource research impact
has been secured, the next step will be the actual produc-
tion of a set of metrics and software to mine articles and
bioresource information metadata in order to test which
ones are best performing. More sophisticated factors would
consider some measurements of bioresource quality and
value, including origin of samples and their rareness thatcould also be further devised and integrated into the
indexing system.
To address the need to incentivize the development,
maintenance and sharing of bioresources, a set of princi-
ples, tools and guidelines is required. We conceptualized
and formalized a framework for bioresources management,
use and referencing on which the medical and scientific
community could rely for their research practice. It can
draw on technologies already in use for tracking and evalu-
ation of impact in other science referencing areas. This art-
icle provides the foundations for the creation of the BRIF as
an adequate instrument. It hopes to trigger discussion
among relevant stakeholders and incite the scientific com-
munity to embark in this endeavor.
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